JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Pliant Therapeutics Inc

Cerrado

1.72 1.18

Resumen

Variación precio

24h

Actual

Mínimo

1.61

Máximo

1.74

Métricas clave

By Trading Economics

Ingresos

-6.4M

-56M

Empleados

171

EBITDA

-10M

-59M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+370.59% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

6.8M

104M

Apertura anterior

0.54

Cierre anterior

1.72

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 ago 2025, 23:11 UTC

Ganancias

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 ago 2025, 22:45 UTC

Ganancias

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 ago 2025, 22:39 UTC

Ganancias

Great-West Lifeco Logs Lower 2Q Profit

5 ago 2025, 21:32 UTC

Ganancias

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 ago 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 ago 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 ago 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 ago 2025, 23:19 UTC

Charlas de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 ago 2025, 23:03 UTC

Charlas de Mercado
Ganancias

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 ago 2025, 22:22 UTC

Ganancias

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 ago 2025, 22:21 UTC

Ganancias

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 ago 2025, 22:20 UTC

Ganancias

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 ago 2025, 22:18 UTC

Ganancias

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 ago 2025, 22:17 UTC

Ganancias

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 ago 2025, 22:17 UTC

Ganancias

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 ago 2025, 22:16 UTC

Ganancias

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 ago 2025, 22:16 UTC

Ganancias

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 ago 2025, 22:15 UTC

Ganancias

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 ago 2025, 22:13 UTC

Ganancias

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 ago 2025, 22:13 UTC

Ganancias

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 ago 2025, 22:12 UTC

Ganancias

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 ago 2025, 22:12 UTC

Ganancias

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 ago 2025, 21:58 UTC

Ganancias

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 21:30 UTC

Ganancias

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 ago 2025, 21:26 UTC

Ganancias

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 ago 2025, 21:23 UTC

Ganancias

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 ago 2025, 21:17 UTC

Ganancias

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

370.59% repunte

Estimación a 12 Meses

Media 8 USD  370.59%

Máximo 17 USD

Mínimo 3 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

1

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.